These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 28740360)

  • 21. Visual mismatch negativity elicited by facial expressions: new evidence from the equiprobable paradigm.
    Li X; Lu Y; Sun G; Gao L; Zhao L
    Behav Brain Funct; 2012 Feb; 8():7. PubMed ID: 22300600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An efficacy analysis of anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to multifocal choroiditis and comparison with wet age-related macular degeneration.
    Feng L; Hu JH; Chen J; Xie X
    J Zhejiang Univ Sci B; 2018 Apr.; 19(4):327-332. PubMed ID: 29616508
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SAVE-AMD: Safety of VEGF Inhibitors in Age-Related Macular Degeneration.
    Enseleit F; Michels S; Sudano I; Stahel M; Zweifel S; Schlager O; Becker M; Winnik S; Nägele M; Flammer AJ; Neidhart M; Graf N; Matter CM; Seifert B; Lüscher TF; Ruschitzka F
    Ophthalmologica; 2017; 238(4):205-216. PubMed ID: 28866675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. UNTREATED OBSTRUCTIVE SLEEP APNEA HINDERS RESPONSE TO BEVACIZUMAB IN AGE-RELATED MACULAR DEGENERATION.
    Schaal S; Sherman MP; Nesmith B; Barak Y
    Retina; 2016 Apr; 36(4):791-7. PubMed ID: 26841211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH ADVANCED VISUAL LOSS TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: Clinical Outcome and Prognostic Indicators.
    Vogel RN; Davis DB; Kimura BH; Rathinavelu S; Graves GS; Szabo A; Han DP
    Retina; 2017 Feb; 37(2):257-264. PubMed ID: 27429385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Effect of Treatment Discontinuation During the COVID-19 Pandemic on Visual Acuity in Exudative Neovascular Age-Related Macular Degeneration: 1-Year Results.
    Stattin M; Ahmed D; Graf A; Haas AM; Kickinger S; Jacob M; Krepler K; Ansari-Shahrezaei S
    Ophthalmol Ther; 2021 Dec; 10(4):935-945. PubMed ID: 34374028
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Face recognition in age related macular degeneration: perceived disability, measured disability, and performance with a bioptic device.
    Tejeria L; Harper RA; Artes PH; Dickinson CM
    Br J Ophthalmol; 2002 Sep; 86(9):1019-26. PubMed ID: 12185131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab.
    Cho H; Shah CP; Weber M; Heier JS
    Br J Ophthalmol; 2013 Aug; 97(8):1032-5. PubMed ID: 23766432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The importance of monitoring wet age-related macular degeneration patients during Coronavirus disease 19 pandemic: A retrospective study of assessment of functional and structural outcomes.
    Tsiropoulos GN; Vallee R; Gallo Castro D; Ambresin A
    J Fr Ophtalmol; 2022 Oct; 45(8):852-859. PubMed ID: 35908993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fellow Eye Comparisons for 7-Year Outcomes in Ranibizumab-Treated AMD Subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study).
    Bhisitkul RB; Desai SJ; Boyer DS; Sadda SR; Zhang K
    Ophthalmology; 2016 Jun; 123(6):1269-77. PubMed ID: 26996339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.
    Ho VY; Yeh S; Olsen TW; Bergstrom CS; Yan J; Cribbs BE; Hubbard GB
    Am J Ophthalmol; 2013 Jul; 156(1):23-28.e2. PubMed ID: 23664153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration.
    Aisenbrey S; Ziemssen F; Völker M; Gelisken F; Szurman P; Jaissle G; Grisanti S; Bartz-Schmidt KU
    Graefes Arch Clin Exp Ophthalmol; 2007 Jul; 245(7):941-8. PubMed ID: 17186262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Visual outcomes and growth factor changes of two dosages of intravitreal bevacizumab for neovascular age-related macular degeneration: a randomized, controlled trial.
    Lai TY; Liu DT; Chan KP; Luk FO; Pang CP; Lam DS
    Retina; 2009 Oct; 29(9):1218-26. PubMed ID: 19934816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk, Prevalence, and Progression of Glaucoma in Eyes With Age-Related Macular Degeneration Treated With Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
    Shah SM; Boopathiraj N; Starr MR; Dalvin LA; AbouChehade J; Damento G; Garcia MD; Hodge DO; Bakri SJ; Sit AJ; Iezzi R
    Am J Ophthalmol; 2022 Nov; 243():98-108. PubMed ID: 35932820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
    Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
    Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration.
    Yuzawa M; Fujita K; Wittrup-Jensen KU; Norenberg C; Zeitz O; Adachi K; Wang EC; Heier J; Kaiser P; Chong V; Korobelnik JF
    Ophthalmology; 2015 Mar; 122(3):571-8. PubMed ID: 25439429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Domain specificity versus expertise: factors influencing distinct processing of faces.
    Carmel D; Bentin S
    Cognition; 2002 Feb; 83(1):1-29. PubMed ID: 11814484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).
    Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
    Graefes Arch Clin Exp Ophthalmol; 2007 Sep; 245(9):1273-80. PubMed ID: 17333238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis.
    Ba J; Peng RS; Xu D; Li YH; Shi H; Wang Q; Yu J
    Drug Des Devel Ther; 2015; 9():5397-405. PubMed ID: 26451092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of intravitreal aflibercept in Japanese patients with exudative age-related macular degeneration.
    Saito M; Kano M; Itagaki K; Sekiryu T
    Jpn J Ophthalmol; 2017 Jan; 61(1):74-83. PubMed ID: 27660164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.